Combined Angiogenesis and Proliferation Markers' Expressions as Long-Term Prognostic Factors in Renal Cell Cancer

Virman, Juha; Bono, Petri; Luukkaala, Tiina; Sunela, Kaisa; Kujala, Paula; Kellokumpu-Lehtinen, Pirkko-Liisa

doi:10.1016/j.clgc.2015.12.014

Cited by 10 publications

(10 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The remaining articles were further excluded for several reasons, such as no data available (hazard ratio [HR] and 95% confidence interval [CI]), low-quality studies17, and duplicate publication. Finally, 20 articles published from 2000 to 2016 with 5,398 patients satisfied the criteria for meta-analysis1112131415161819202122232425262728293031. A flowchart of the study selection process is shown in Fig.…”

Section: Resultsmentioning

confidence: 99%

“…However, the role of Ki-67 in the prognosis of RCC remains inconsistent. Ki-67 was considered an unfavorable prognostic marker in RCC in many studies11121314, but some studies reported that Ki-67 expression is prognostically irrelevant in RCC patients1516. To obtain a more precise evaluation of the prognostic and clinicopathological value of Ki-67 expression in RCC, we performed a systematic review and meta-analysis to evaluate the prognostic value of Ki-67 quantitatively and explore the associations of Ki-67 with the clinicopathological features of RCC.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Prognostic and clinicopathological role of high Ki-67 expression in patients with renal cell carcinoma: a systematic review and meta-analysis

Xie

Chen

et al. 2017

Sci Rep

View full text Add to dashboard Cite

Previous studies have elevated the prognostic value of Ki-67 in renal cell carcinoma (RCC), but the reports are controversial and inconsistent. We conducted a systematic review and meta-analysis to clarify the significance of Ki-67 in RCC prognosis. We systematically searched PubMed, Web of Science, and Embase to identify relevant studies until April 2016. Based on the inclusion and exclusion criteria, 20 studies, including 5,398 patients, were eligible for further analysis. Results showed that high Ki-67 expression in RCC was associated with poor OS (HR = 1.95, 95% CI: 1.44–2.64), CSS (HR = 1.67, 95% CI: 1.47–1.89), and DFS (HR = 2.56, 95% CI: 1.79–3.67). In addition, high Ki-67 expression was significantly associated with TNM stage (III/IV vs. I/II: RR = 2.03, 95% CI: 1.68–2.44), pathological T stage (T3/T4 vs. T1/T2: RR = 1.67, 95% CI: 1.35–2.06), metastasis (yes vs. no: RR = 2.15, 95% CI: 1.77–2.62), and Fuhrman grade (III/IV vs. I/II: RR = 1.77, 95% CI: 1.20–2.60). Our study suggested that Ki-67 was a prognostic marker in RCC. High Ki-67 expression was correlated with poor prognosis and advanced clinicopathological features, and it could serve as a biomarker for disease management.

show abstract

Section: Resultsmentioning

confidence: 99%

mentioning

confidence: 99%

Prognostic and clinicopathological role of high Ki-67 expression in patients with renal cell carcinoma: a systematic review and meta-analysis

Xie

Chen

et al. 2017

Sci Rep

View full text Add to dashboard Cite

show abstract

“…Then 15 articles were excluded (2 articles were duplicate studies, 12 lacked key information, and 1 did not measure Ki-67 expression by IHC). At last, 23 studies 12 – 34 published from 2000 to 2016 with 4579 patients met our inclusion criteria and were included in the meta-analysis.…”

Section: Resultsmentioning

confidence: 99%

“…The sample size ranged from 43 to 741. Nineteen studies were conducted in non-Asian countries, including France, 12 Finland, 22 , 28 , 33 , 34 Germany, 18 , 29 , 30 Italy, 25 Sweden, 27 and USA. 13 , 15 – 17 , 20 , 21 , 24 , 26 , 31 Four studies were conducted in Asian countries, including China, 32 Turkey, 19 and Japan.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Prognostic and clinicopathological value of Ki-67/MIB-1 expression in renal cell carcinoma: a meta-analysis based on 4579 individuals

Wang¹,

Xie²,

Guo³

et al. 2017

CMAR

View full text Add to dashboard Cite

BackgroundPrevious studies have investigated the prognostic significance of Ki-67/MIB-1 expression in renal cell carcinoma (RCC), however, the reports are controversial and inconsistent. This study aimed to investigate Ki-67/MIB-1 expression in RCC and its correlation with prognosis and clinicopathological features.MethodsWe searched relevant studies that reported associations between Ki-67/MIB-1 expression and prognosis in RCC from PubMed, Embase, Web of Science, and Cochrane Library studies published until April 14, 2017. Hazard ratios (HRs) and 95% confidence intervals (CIs) were extracted from eligible studies. Fixed and random effects models were used to calculate pooled HRs and 95% CIs according to heterogeneity.ResultsA total of 4579 participants from 23 eligible studies were included in this analysis. The results showed that Ki-67/MIB-1 expression was associated with poor overall survival (HR=2.06, 95% CI: 1.64–2.57) and cancer specific survival (HR=2.01, 95% CI: 1.66–2.44). In addition, Ki-67/MIB-1 expression was also correlated with TNM stage (III/IV vs I/II: OR=1.92, 95% CI: 1.61–2.28), pathological T stage (pT3/pT4 vs pT1/pT2: OR=1.56, 95% CI: 1.21–2.02), distant metastasis (M1 vs M0: OR=1.81, 95% CI: 1.34–2.43), and Fuhrman grade (III/IV vs I/II: OR=1.94, 95% CI: 1.21–3.10).ConclusionOur study demonstrates that the presence of high Ki-67/MIB-1 expression and advanced clinicopathological features were correlated with poor prognosis in RCC patients.

show abstract

Biomarkers of Renal Tumors: the Current State and Clinical Perspectives

et al. 2017

View full text Add to dashboard Cite

Renal cell carcinoma (RCC) ranks the first death rate among the urogenital tumors, whereas its incidence follows the incidences of prostate and bladder cancer. The diagnosis of RCC at early stages allows immediately undertaking appropriate treatment, which significantly increases patients' survival rate. Early and accurate diagnosis avoids inadequate treatment, provides the disease progression forecast, and permits to apply more efficient therapy. Unfortunately, the small renal tumors are usually asymptomatic resulting in the late diagnosis and, therefore, low efficacy of treatment. Thus, sensible and preventive biomarkers are essential for early RCC detection and monitoring of its progression. So far, many attempts were performed aimed at recognizing novel informative kidney tumor biomarkers applicable for early detection of the disease and possessing prognostic and predictive capabilities. This review summarizes recent advances in renal tumor biomarkers recognition, their diagnostic and prognostic values, and clinical feasibility.

show abstract

Combined Angiogenesis and Proliferation Markers' Expressions as Long-Term Prognostic Factors in Renal Cell Cancer

Cited by 10 publications

References 38 publications

Prognostic and clinicopathological role of high Ki-67 expression in patients with renal cell carcinoma: a systematic review and meta-analysis

Prognostic and clinicopathological role of high Ki-67 expression in patients with renal cell carcinoma: a systematic review and meta-analysis

Prognostic and clinicopathological value of Ki-67/MIB-1 expression in renal cell carcinoma: a meta-analysis based on 4579 individuals

Biomarkers of Renal Tumors: the Current State and Clinical Perspectives

Contact Info

Product

Resources

About